We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00590096
First Posted: January 10, 2008
Last Update Posted: August 25, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Cincinnati
Information provided by:
Children's Hospital Medical Center, Cincinnati
December 27, 2007
January 10, 2008
August 25, 2009
January 1991
December 2008   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00590096 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors

Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma.

Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide

Observational
Observational Model: Case-Only
Not Provided
Not Provided
Non-Probability Sample
Patients with histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma
  • Neuroblastoma
  • Pheochromocytoma
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1380
December 2008
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma

Exclusion Criteria:

  • Pregnancy
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00590096
CCHMC# 88-12-2
No
Not Provided
Not Provided
Michael J. Gelfand M.D., Cincinnati Children's Hospital
Children's Hospital Medical Center, Cincinnati
University of Cincinnati
Principal Investigator: Michael J Gelfand, M.D. Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati
January 2007